# Inhibitors of arachidonic acid metabolism reduce DNA and nuclear fragmentation induced by TNF plus cycloheximide in U937 cells

Daina M Vanags<sup>1</sup>, Pontus Larsson<sup>2</sup>, Stina Feltenmark<sup>2</sup>, Per-Johan Jakobsson<sup>2</sup>, Sten Orrenius<sup>1</sup>, Hans-Erik Claesson<sup>2</sup> and Miguel Aguilar-Santelises<sup>1</sup>

- <sup>1</sup> Division of Toxicology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden
- <sup>2</sup> Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
- <sup>3</sup> corresponding author: M Aguilar-Santelises, M.D. Institute of Environmental Medicine, Division of Toxicology, Karolinska Institute, Box 210, S-171 77, Stockholm, Sweden. fax: -46-8-32-59-86

Received 29.11.96; revised 6.3.97; accepted 10.4.97 Edited by P. Cohen

# Abstract

U937 human myeloid leukemia cells are induced to apoptosis by tumour necrosis factor (TNF) plus cycloheximide (CHX). We have analysed the effect of various inhibitors of the arachidonic acid (AA) metabolism on several features of this process. The formation of high molecular weight and oligonucleosomal DNA fragments as well as nuclear fragmentation were reduced by inhibitors of 5-lipoxygenase (BWA4C and BWB70C), 5-LO activating protein (MK-886), and cytosolic PLA<sub>2</sub> (AACOCF<sub>3</sub>). None of these agents blocked the morphological changes detected by microscopy or flow cytometry, phosphatidylserine exposure on the cell surface or Caspase 3-like activation. AA also induced nuclear fragmentation at a concentration of  $1-20 \mu$ M. However, the mechanisms by which these inhibitors act, remain unexplained since there was no 5-LO expression in the U937 cells and no AA release followed their stimulation with TNF plus CHX.

**Keywords:** arachidonic acid, cytosolic phospholipase A<sub>2</sub>, 5-lipoxygenase, TNF, U937, apoptosis

**Abbreviations:** MW, molecular weight; CHX, cycloheximide; TNF, tumour necrosis factor, 5-LO, 5-lipoxygenase; FLAP, 5lipoxygenase activating protein; cPLA<sub>2</sub>, cytosolic PLA<sub>2</sub>; PS, phosphatidylserine; AA, Arachidonic acid; ICE, interleukin-1 $\beta$ converting enzyme; 5-HPETE, 5-hydroperoxy-eicosatetraenoic acid; 5-HETE, 5-hydro-eicosatetraenoic acid LTA<sub>4</sub>, leukotriene A<sub>4</sub>; LTB<sub>4</sub>, leukotriene B<sub>4</sub>; PGH-1, prostaglandin-1 synthase or cyclo-oxygenase-1; PGH-2, prostaglandin-2 synthase or cyclo-oxygenase-2; DEVD-AMC, Ac-Asp-Glu-Val-Asp-amino-4-methylcoumarin; DEVD-CHO or aldehyde, Ac-Asp-Glu-Val-Asp-CHO

## Introduction

Tumour necrosis factor (TNF, also known as cachectin or  $\text{TNF}_{\alpha}$ ) is a polypeptide mediator of inflammation and cellular immune responses (Aggarwal and Natarajan, 1996). Upon binding to its cell surface receptor, TNF initiates apoptosis and the transcription of protective genes by processes that are not yet well understood (Beyaert and Fiers, 1994). Apoptosis is an intrinsic suicide mechanism that occurs as consequence of physiological or pathological processes (Fraser and Evan, 1996). It can be induced by diverse stimuli which cause characteristic morphological and biochemical changes leading to cell death (Steller, 1995).

TNF induces the activation of interleukin-1 $\beta$ -converting enzyme (ICE)-like proteases such as CPP32 (caspase 3) which appear to be essential for the cell death mechanism (Tewari *et al*, 1995; Zhivotovsky *et al*, 1996). TNF also induces a number of cell signals that include activation of cytosolic Ser/Thr protein kinases (Beyaert and Fiers, 1994), and phospholipase A<sub>2</sub> (PLA<sub>2</sub>) (Neale *et al*, 1988; Hollenback *et al*, 1992; McEwan, 1996), ceramide production and superoxide radical generation (Aggarwal and Natarajan, 1996). The ability of TNF to induce AA release and activate the enzymes involved in its metabolism, has prompted the suggestion that this pathway may be an important regulator of cell survival (Schutze *et al*, 1992; Tang *et al*, 1996; Voelkel-Johnson *et al*, 1996).

Arachidonic acid (AA) metabolism begins with cPLA<sub>2</sub> catalysing the release of AA from cell membrane phospholipids (Dennis, 1994). 5-Lipoxygenase (5-LO) catalyses the conversion of AA to 5-hydroperoxy-eicosatetraenoic acid (5-HPETE) which can be degraded either to 5-hydroxyeicosatetraenoic acid (5-HETE) or leukotriene A<sub>4</sub> (LTA<sub>4</sub>), that can then be metabolised to LTB<sub>4</sub>. Other important contributors to AA metabolism include 5-LO activating protein (FLAP), which is required for optimal cellular leukotriene synthesis (Claesson et al, 1992) and prostaglandin (PGH) synthases (also known as cyclooxygenases) which catalyse the conversion of AA to prostaglandins and thromboxanes (Hamberg et al, 1975). The effect of various PLA2, lipoxygenase (LO) and prostaglandin synthase (PGH-synthase) inhibitors is unclear, since they have been associated both with induction of (Anderson et al, 1993, 1995; Tsujii and Dubois, 1995; Tang et al, 1996) and protection from apoptosis (Chang et al, 1992; Agarwal et al, 1993; O'Donnell et al, 1995).

To investigate the link between AA metabolism and apoptosis, we have studied the events that occur when U937 cells are exposed to TNF plus cycloheximide (CHX). Previous studies have used non-specific inhibitors such as NDGA, which is an antioxidant that can inhibit both LO and PGH synthases (Chang *et al*, 1992; O'Donnell *et al*, 1995). Instead, we have studied the effect of the until now considered specific 5-LO inhibitors BW A4C and BW B70C. We have also used MK-886, a FLAP inhibitor that interferes with substrate binding to 5-LO (Gillard *et al*, 1989; Ford-Hutchinson *et al*, 1994), and AACOCF<sub>3</sub>, a specific inhibitor of cPLA<sub>2</sub> (Riendeau *et al*, 1994). Here, we report that these compounds inhibit nuclear but not cytoplasmic features of apoptosis induced by TNF plus CHX in U937 cells.

## Results

#### Induction of apoptosis

TNF plus CHX induced features of apoptosis in U937 cells, occurring simultaneously with trypan blue exclusion over a 5 h time course. U937 cells were analyzed by FACS (Figure 1). Changes in forward scatter (FSC) and side scatter (SSC) were apparent after 2 h incubation with TNF plus CHX. The number of cells in gate 1 (to the right) decreased, with correspondent increasing values in gate 2 (to the left), which included cell fragments and cells with diminished size (Figure 1A). From 10 000 cells that were originally in gate 1, there was a decrease to  $5956 \pm 1575$  cells at 5 h, which was significantly different (n=4; P<0.05) when compared to cells incubated with ethanol alone. However, the effect of incubating U937

cells with TNF plus CHX and the inhibitors was not different from the effect induced by TNF plus CHX alone (Figure 1B).

#### PS exposure

PS exposure was detected using FITC-Annexin binding assay, after 2 h treatment of U937 with TNF plus CHX. Again, no inhibitory effect on annexin binding was obtained when TNF plus CHX-stimulated cells were incubated in the presence of the inhibitors as illustrated with AACOCF3 in Figure 2.

#### **Caspase 3-like activity**

TNF plus CHX stimulated an increase in Caspase 3-like enzyme activity in U937 cells after 90 min (Table 1), which is inhibitable by DEVD-CHO, a specific inhibitor of Caspase 3-like enzymes (Vanags *et al*, 1996). Inhibitors of AA metabolism were incubated with U937 cells in culture stimulated with TNF and CHX, but none of the inhibitors had a significant effect on Caspase 3-like enzyme activity (Table 1).

# 5-LO, FLAP and $cPLA_2$ inhibitors reduce nuclear and DNA fragmentation

TNF plus CHX induced nuclear fragmentation which was increased over the 5 h time course (Figure 3). However, the

B



**Figure 1** Cellular fragmentation and shrinkage. U937 cells were collected at different time points during incubation with TNF (12 ng/ml) plus CHX (1  $\mu$ g/ml), and analyzed by flow cytometry. (**1A**) shows dot plots corresponding to 0, 1, 3 and 5 h (from top to bottom). 10 000 cells were analyzed by linear FSC *vs* logarithmic SSC. Gate 1 (to the right) includes cells with the initial morphology, while Gate 2 (to the left) includes cells with altered size and density. (**1B**) shows cell numbers in Gate 1 (continuous lines) and Gate 2 (discontinuous lines) during the 5 h incubation with ethanol ( $\Box$ ) or TNF plus CHX, alone (**T**) or in the presence of BW A4C (X), BW B70C ( $\triangle$ ), MK-886 (+), and AACOCF<sub>3</sub> ( $\bigtriangledown$ ).

number of cells with nuclear fragmentation was decreased when they were incubated in the presence of 5-LO, FLAP and cPLA<sub>2</sub> inhibitors. This inhibition was dose dependent, with maximal effect at 10  $\mu$ M concentration of each one of the inhibitors (*P*<0.05, Figure 4).

Treatment with TNF plus CHX also induced the formation of high MW and oligonucleosomal DNA fragments. DNA fragmentation was inhibited when the cells were incubated in the presence of BWA4C, BWB7OC, and



Mean Fluorescence Intensity

**Figure 2** PS exposure on the surface of U937 cells. (**A**) Annexin V-FITC binding from U937 cells not treated (continuous line) or treated with TNF plus CHX (dotted line). (**B**) Annexin V-FITC binding of TNF plus CHX treated cells in the presence (continuous line) or in the absence (dotted line) of AACOCF<sub>3</sub>.

Table	1	DEVD-AMC	cleavage	in	U937	cells
10010			oloutago		0001	00110

	AMC released (pmoles/min)
Medium	2.0±0.5
Ethanol	3.0±1.0
TNF plus CHX	24.0±12.0
TNF plus CHX and BW A4C	$26.0 \pm 11.0$
TNF plus CHX and BW B70C	21.0±11.0
TNF plus CHX and MK-886	$24.0 \pm 13.0$
TNF plus CHX and AACOCF <sub>3</sub>	$20.0\pm9.0$

DEVD-AMC cleavage was assessed in a kinetic assay monitoring pmol of AMC released over time. V<sub>0</sub> maximum (pmoles/min) was estimated from linear regressions (r<sup>2</sup>>0.99) after U937 cells were incubated with the inhibitors (10  $\mu$ M). Data are mean $\pm$ s.e. of three experiments done in triplicate.



Figure 3 Percentage of nuclear fragmentation induced in U937 cells during 5 h time course incubation with TNF (12 ng/ml) plus CHX (1  $\mu$ g/ml).

MK-886 in a range of concentrations between 0.1 and 10  $\mu$ M (Figure 5A and B). High MW DNA fragments were decreased in the presence of 1  $\mu$ M AACOCF<sub>3</sub>, but not in the presence of ethanol alone. Incubating the cells with TNF, CHX or the inhibitors alone did not result in DNA fragmentation (not shown).

#### Enzyme expression by RT-PCR

The expression of the key enzymes for AA degradation was analysed at transcriptional level. Our U937 cell clone was positive for  $\beta$  actin, cPLA<sub>2</sub>, FLAP, LTA<sub>4</sub> and PGH-1



**Figure 4** Percentage of nuclear fragmentation in U937 cells induced by TNF (12 ng/ml) plus CHX (1  $\mu$ g/ml) after 3h in the presence of BW A4C (**A**), BW B70C (**B**), MK-886 (**C**), or AACOCF<sub>3</sub> (**D**). Inhibition reached statistical significance (*n*=4, *P*<0.05) with every compound at 10  $\mu$ M concentration.



>Figure 5 Analysis of high MW (A) and oligonucleosomal (B) DNA fragments. Lane 1 corresponds to MW marker from 0.1 to 200 kb, lane 2 to MW marker from 225 to 2200 kb, and lane 3 to U937 cells incubated with ethanol 0.1%. U937 cells were incubated with TNF (12 ng/ml) plus CHX (1 µg/ml) alone (lane 4), or in the presence of BW A4C (lanes 5, 6, 7), BW B70C (lanes 8, 9, 10), or MK-886 (lanes 11, 12, 13) at 0.1 µM, 1 µM and 10 µM. U937 were also incubated with TNF plus CHX and 1 µM AACOCF<sub>3</sub> (lane 14).



**Figure 6** Analysis of cDNA from U937 cells by RT-PCR. Lane 1 corresponds to a 123 bp molecular marker, and the following lanes correspond to  $\beta$  actin (2), cPLA<sub>2</sub> (3), 5-LO (4), FLAP (5), LTA<sub>4</sub> hydrolase (6), PGH-1 synthase (7) and PGH-2 synthase (8). Positive amplification of the BL41-E95-A lymphoma cell line for 5-LO is shown in lane 9.

synthase, whereas it was negative for 5-LO and PGH-2 synthase (Figure 6). There was no 5-LO protein detected by Western blot and no leukotriene synthesis was found by HPLC (not shown). Positive 5-LO amplification was obtained with cDNA from the BL41-E95-A lymphoma cell line (Figure 6). Positive amplification for PGH-2 was

obtained with cDNA from normal human leukocytes and from human umbilical cord vein endothelial cells (not shown).

# cPLA<sub>2</sub> inhibition by BW A4C, BW B70C, MK-886 and AACOCF<sub>3</sub>

BW A4C and BW B70C, as well as MK-886, are considered selective inhibitors for 5-LO (Garland and Hodgson, 1994) and FLAP, respectively (Ford-Hutchinson et al, 1994). However, we found that the three compounds partially inhibited cPLA<sub>2</sub> activity, purified approximately 500-fold from U937 cells, at the same concentrations that were effective for inhibition of apoptosis (not shown). AACOCF<sub>3</sub> was the most potent cPLA<sub>2</sub> inhibitor, allowing only  $7.9\pm0.2\%$  of the activity from the control, when present at 1 µM concentration. AACOCF<sub>3</sub> decreased also cPLA<sub>2</sub> activity in the presence of TNF plus CHX in total cellular homogenates (Figure 7). However, we could not find an increase in cPLA<sub>2</sub> activity in the homogenate of cells stimulated with TNF plus CHX after short (0 to 10 min; Figure 7) or long time exposure (0 to 3 h; not shown). We did neither find AA release from intact U937 cells stimulated with TNF plus CHX, both in the presence or in the absence of serum (not shown).

#### Apoptosis induction by AA

In order to investigate whether AA itself could induce apoptosis, we incubated U937 cells with AA at various





Table 2 Nuclear fragmentation induced by AA

	0 h	1 h	3 h	5 h
medium	5.4*	8.2	10.3	12.9
TNF+CHX		4.4	47.7	51.4
1 μ <b>Μ ΑΑ</b>		2.7	11.4	14.3
10 μM AA		11.5	13.7	25.6
20 µM AA		4.6	24.4	36.5

\*Percentage of cells having nuclear fragmentation, as determined by Hoechst 33342 staining. Data are from a representative experiment performed in duplicate.

cPLA<sub>2</sub> plays an important role in basal phospholipid metabolism and signal transduction (Dennis, 1994). We found that BW A4C, BW B70C, MK-886 and AACOCF<sub>3</sub> partially inhibited basal cPLA<sub>2</sub> activity in U937 cells. Recent studies have implicated cPLA<sub>2</sub> in lymphocyte maturation (Feltenmark et al, 1995) and apoptosis (Gilbert et al, 1996). It is plausible that basal rather than TNF-stimulated cPLA<sub>2</sub> activity is an important homeostatic mechanism. The capacity of these compounds to inhibit apoptosis could be due to interference with basal cPLA<sub>2</sub> activity.

Although we did not find an increase in cPLA<sub>2</sub> activity or AA release, as consequence of TNF plus CHX stimulation, there was a clear induction of nuclear fragmentation following incubation of U937 cells with AA. Our results differ from previous reports describing an increase in PLA<sub>2</sub> activity and AA release after TNF plus CHX treatment in various cell types, including U937 (Neale et al, 1988; McEwan, 1996; Voelkel-Johnson et al, 1996). Our inability to detect AA release from intact cells could be explained by a rapid, transient or variable rise in AA, reincorporation of AA into cellular lipids by reacylation (Cissel et al, 1996), or clonal diversity (Withnall et al, 1995).

Other studies indicate that cPLA<sub>2</sub> and 5-LO are translocated to the nuclear membrane after activation of peritoneal macrophages by ionophore A23187 (Peters-Golden and McNish, 1993). 5-LO is primarily nuclear membrane bound in human B-lymphocytes (Jakobsson et al, 1995), and PGH synthase I and PGH synthase II are also localised at this site (Regier et al, 1993). Furthermore, it has been reported that AA released after receptor stimulation originates from nuclear membrane phospholipids (Capriotti et al, 1988). AA metabolites are important messengers for signalling between cells. It is also possible that AA or its metabolites have a significant role within cells by transmitting signals to the nucleus. cPLA<sub>2</sub> translocation to nuclear membranes during apoptosis could explain the lack of detectable AA in the present study.

The relative importance of nuclear and cytosolic events in the development of apoptosis remains controversial. Chromatin condensation and nuclear fragmentation can be observed in cell free systems, and membrane and cytosolic alterations occur in enucleated cells (Schultze-Osthoff et al, 1994; Newmeyer et al, 1994). Although further work is necessary to define interactions between apoptosis and AA metabolism, the ability of these inhibitors to interfere with cPLA<sub>2</sub> activity and DNA fragmentation may be an important tool to make a distinction between cytoplasmic and nuclear events that lead to cell death.

PLA<sub>2</sub> activity 5 0 0 2 5 min 10 Figure 7 cPLA<sub>2</sub> activity in U937 cell homogenates. Cells were stimulated for the indicated times, and thereafter homogenised. The activity is expressed as

concentrations for increasing periods of time. AA induced a significant nuclear fragmentation, dose and time dependent, although not as much as that induced by TNF plus CHX

released pmol <sup>14</sup>C-20:4/mg protein/min. Graphs correspond to cPLA<sub>2</sub> activity

of untreated (●-●-●), TNF plus CHX treated (■--■--■) or TNF plus CHX

treated cells, preincubated with  $10 \,\mu M$  AACOCF<sub>3</sub> ( $\bullet$  -  $\bullet$  -  $\bullet$ ).

## Discussion

(Table 2).

10

In the present study we have shown that BW A4C, BW B70C, MK-886, and AACOCF3 inhibit nuclear events in U937 cells undergoing apoptosis. Since U937 cells do not produce leukotrienes and lack 5-LO (Claesson et al, 1993), neither 5-LO or FLAP inhibition could explain the inhibition of apoptosis by these compounds. At the concentration range used BW A4C, BW B70C and MK-886, like AACOCF<sub>3</sub> also inhibited cPLA<sub>2</sub> enzyme activity. Furthermore, we have shown that AA, the product of cPLA<sub>2</sub> activation is able to induce apoptosis in U937 cells. However, we failed in demonstrating an increase in cPLA<sub>2</sub> activity or extracellular AA release after treatment of U937 with TNF plus CHX. Although the effect of these inhibitors may help to make a distinction between nuclear and cytoplasmic events of apoptosis, their mechanisms of action remain an open question.

BW A4C and BW B70C, are analogues of AA containing an hydroxamic acid (BW A4C) or N-hydroxyurea (BW B70C) group linked to a lipophilic aryl unit. They seem to inhibit 5-LO by scavenging lipid peroxides at the active site of the enzyme (Garland and Hodgson, 1994). MK-886, a thiopyranindole structure is also considered a selective inhibitor of the 5-LO pathway and acts by binding to FLAP and inhibiting 5-LO translocation to nuclear membranes. MK886 has been described as not affecting 5-LO or PLA<sub>2</sub> (Gillard et al, 1989; Ford-Hutchinson et al, 1994), although we have shown that it does in fact inhibit cPLA<sub>2</sub> activity. This discrepancy might be due to different assay systems used for the determination of cPLA<sub>2</sub> activity. Mechanistically, it is likely that the lipophilic aryl moiety localises the inhibitors in the phase of the cell membrane at which cPLA2 is active (Garland and Hodgson, 1994) and probably interferes directly with the cPLA<sub>2</sub> enzyme, independent of substrate concentration (Tanaka et al, 1992).

# Materials and Methods

#### Reagents

Human TNF was a kind gift from Dr Grace Wong (Genentech Inc., San Francisco, CA). MK-886 was kindly given by Dr Anthony Ford-Hutchinson (Merck Frosst Centre for Therapeutic Research; Quebec, Canada). BW A4C and BW B70C were kindly donated by Dr Lawrence G. Garland (Wellcome Research Laboratories; Kent, UK). AACOCF<sub>3</sub>, 5-HPETE and arachidonic acid were from Biomol (Plymouth Meeting, PA). CHX, poly-L-Lysine, trypan blue, propidium iodide, and phorbol 12-myristate 13-acetate were from Sigma Chemical (St. Louis, MO). Hoechst 33342 was from Molecular Probes Inc. (Eugene, OR). Apoptest was purchased from Nexins (Hoeven, Netherlands). Phenol, chloroform, DTT, HEPES and sucrose were purchased from Fluka (Buchs, Switzerland). RNAsin and Tag polymerase were from SDS (Falkenberg, Sweden). DTT, Moloney murine leukemia virus reverse transcriptase (M-MLV RT) and first strand buffer were from GIBCO BRL (Gaithersburg, MD). Random primers (pd(N)6), ultrapure dNTP and agarose NA were obtained from Pharmacia AB (Uppsala, Sweden). HPLC solvents were purchased from Rathburn Chemicals (Walkerburn UK). Monoflow 2 scintillation liquid was obtained from National Diagnostics (Manville, NJ). 1-palmitoyl 2-[1-14C]arachidonyl phosphatidylcholine (PC) was obtained from New England Nuclear (Dierech, Germany). FPLC System and protein purification columns were from Pharmacia Biotech (Uppsala, Sweden). DEVD-AMC was from Bachem (Bubendorf, Switzerland).

#### Cell culture

The U937 human monoblastoid cell line was cultured in RPMI 1640 medium supplemented with 10% FCS, 2 mM glutamine, penicillin and streptomycin in a humidified atmosphere of 5% CO<sub>2</sub> in air at 37°C (Sundstrom and Nilsson, 1976). Cells were kept undifferentiated by culturing for short periods and thawing a fresh aliquot of cells every three months. Cells were incubated at  $1 \times 10^6$ /ml in six well plates, during 5 h in the presence or in the absence of TNF (12 ng/ml) plus CHX (1  $\mu$ g/ml). 5-LO, FLAP and cPLA<sub>2</sub> inhibitors were added 5 min before TNF plus CHX, at concentrations between 0.1  $\mu$ M and 10  $\mu$ M and were present in the correspondent cultures during the whole experiment. Cell viability was analyzed at various time points by trypan blue exclusion.

#### Flow cytometry

After incubation with or without TNF plus CHX and the various inhibitors, cells were fixed with 4% PFA, at various time points. Samples were analyzed by flow cytometry (FACS) using a Becton Dickinson FACScan flow cytometer equipped with a 15 mW, 488 nm air cooled argon laser. 10 000 cells were acquired for each determination, with a rate lower than 400 events/sec.

#### Phosphatidylserine (PS) exposure

PS exposure during apoptosis was quantitated by measuring the binding of annexin V-FITC with the Apoptest binding kit (Dachary-Prigent *et al*, 1993). Cells were stained with annexin V-FITC and propidium iodide (PI, 100  $\mu$ g/ml) and analyzed by flow cytometry for the simultaneous determination of PS exposure and cell membrane integrity.

#### Caspase 3-like activation

Caspase 3-like enzyme activity was measured by the ability to cleave the peptide substrate Asp-Glu-Val-Asp (DEVD) linked to amino-4methylcoumarin (AMC) in a fluorometric assay modified from Nicholson (Nicholson *et al*, 1995). Cell lysate and substrate were combined in a standard ICE reaction buffer (100 mM HEPES, 10% sucrose, 5 mM DTT, 0.1% CHAPS; pH 7.25). Cleavage was monitored by AMC liberation using 355 nm excitation and 460 nm emission wave lengths. Fluorescence units were converted to pmoles of AMC using a standard curve with increasing doses of AMC against fluorescence (Thornberry *et al*, 1992).

#### **Nuclear fragmentation**

U937 cells were harvested, pelleted and resuspended in 4% paraformaldehyde (PFA) in PBS, in order to spread  $0.3 \times 10^6$  cells on poly-L-lysine (100  $\mu$ g/ml) treated glass microscope slides that were left to dry. Cells were rehydrated and stained with Hoechst 33342 (10  $\mu$ g/ml) for 10 min, rinsed with water, dried in the dark and covered with glycerol/PBS (50/50) and a coverslip. At least 200 cells were analyzed by examining the fluorescent nuclei with a fluorescence microscope.

#### High MW and oligonucleosomal DNA fragments

The presence of High MW DNA fragments was analyzed with field inversion gel electrophoresis (Brown *et al*, 1993). After incubation,  $10^6$  cells were pelleted, resuspended in 50  $\mu$ l PBS and mixed with 50  $\mu$ l of 1% low-melting-point agarose. The agarose plugs were digested for 48 h with pronase (1 mg/ml) at 50°C. High MW DNA fragments were electrophoresed and photographed with UV illumination. Analysis of oligonucleosomal DNA fragments was performed as described by Sorenson (Sorenson *et al*, 1990). After incubation  $10^6$  cells were pelleted, resuspended in 10  $\mu$ l PBS, 5  $\mu$ l RNAse (50 mg/ml) and 5  $\mu$ l loading buffer (0.25% bromophenol blue, 30% glycerol) and 10  $\mu$ l of sample were loaded in a 1.8% agarose gel, with a precast digestion gel containing 2% SDS and 1 mg/ml proteinase K in 0.8% agarose. The gel was electrophoresed overnight at 20 V followed by 3 h at 90 V, and stained with ethidium bromide.

#### RNA extraction, cDNA and PCR amplification

Total RNA was isolated (Chomczynski and Saachi, 1987) and quantitated by spectrophotometry. 2  $\mu$ g RNA were reverse transcribed and tested for PCR amplification with specific primers (Feltenmark *et al*, 1995). 2  $\mu$ l of cDNA were mixed with 46  $\mu$ l of the amplification mixture containing Taq polymerase buffer, 0.2 mM dNTP, 0.5  $\mu$ M each of 5' and 3' primers, 2 U Taq polymerase, and 0.5 mM MgCl<sub>2</sub> (for 5-LO and FLAP) or 1.0 mM MgCl<sub>2</sub> (for  $\beta$  actin, cPLA<sub>2</sub>, LTA<sub>4</sub> hydrolase, PGH synthase 1 and PGH synthase 2). PCR amplification was run for 25 cycles ( $\beta$  actin, LTA<sub>4</sub> hydrolase and FLAP) or 34 cycles (cPLA<sub>2</sub>, 5-LO, PGH synthase 1 and PGH synthase 2) with 60°C as annealing temperature (Feltenmark *et al*, 1995).

$\beta$ actin	5'-GAGGAGCACCCCGTGCTGCTGA-3'	784 bp
	5'-CTAGAAGCATTTGCGGTGG-3'	
cPLA <sub>2</sub>	5'-TTGCAAACTGCCTCAGCATCAG-3'	554 bp
	5'-CTCTAGTCCTCCGTTCAAGGAAC-3'	
5-LO	5'-ACCATTGAGCAGATCGTGGACACGC-3'	488 bp
	5'-GCAGTCCTGCTCTGTGTAGAATGGG-3'	
FLAP	5'-GGCCATCGTCACCCTCATCAGCG-3'	352 bp
	5'-GCCAGCAACGGACATGAGGAACAGG-3'	
LTA <sub>4 hydrolase</sub>	5'-GAACAACTGCTTGGAGGACCAGAG-3'	624 bp
	5'-TGCAGTCACGGGATGCATGCTTGC-3'	
PGH <sub>synthase 1</sub>	5'-CCTACACCTCCTTCCAGGAGCTC-3'	285 bp
	5'-AGACCAGCTTCTTCAGTGTGGCCG-3'	
PGH <sub>synthase 2</sub>	5'-TTCAAATGAGATTGTGGGAAAATTGCT-3'	305 bp
	5'-AGATCATCTCTGCCTGAGTATCTT-3'	

#### Purification of cPLA<sub>2</sub>

Liquid chromatography was performed on a Pharmacia FPLC System. All buffers were made fresh, passed through a 0.22  $\mu$ m filter and degassed before use. U937 cells were sonicated twice for 5 s. The cell homogenate was centrifuged at  $10^5 \times g$  for 60 min to obtain cytosolic and membrane fractions. The  $10^5 \times g$  supernatant, from 25 to 30 mg of protein, obtained from U937 cell homogenate, was applied to a Resource-Q 6 ml column pre-equilibrated with buffer A [20 mM Tris-HCI (pH 7.5), 1 mM EGTA, 1 mM EDTA and 0.5 mM DTT]. After washing, a gradient was developed from 0.2 M to 0.6 M NaCl in buffer A at a flow rate of 3 ml/min. Fractions of 1.5 ml were collected and 15  $\mu$ l aliquots were assayed for cPLA<sub>2</sub> activity. (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> (1 M final concentration) was added to pooled, active fractions from the Resource-Q column and applied to a Phenyl-Superose HR 5/5 column pre-equilibrated with 1 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> in buffer A. Proteins were eluted in a stepwise gradient from 1 M to 0 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> at a flow rate of 0.3 ml/min. Fractions of 0.5 ml were collected and 15  $\mu$ l aliquots of these were assayed for cPLA<sub>2</sub> activity. Thus purified, pooled active fractions were further analyzed for cPLA<sub>2</sub> content by Western blot. This partially purified cPLA<sub>2</sub> was used for activity studies with the different inhibitors. Protein concentrations were measured with a kit against BSA as standard protein (Bio-Rad, USA), essentially according to Lowry et al. (1951).

#### PLA<sub>2</sub> assay

PLA<sub>2</sub> activity was assayed with 1-palmitoyl 2-[1-14C]arachidonyl phosphatidylcholine (PC) as standard substrate. The phospholipid was dried under nitrogen and resuspended in assay buffer [80 mM glycine, (pH 9.0), 5 mM CaCl<sub>2</sub>, 5 mM DTT, 1 mg/ml albumin and 10% glycerol] to yield a final concentration of 2 µM PC. This preparation (57 nCi) was subsequently sonicated in a water bath for 10 min at 4°C. The reaction was initiated by adding either homogenate or purified PLA<sub>2</sub> and the reaction proceeded for 30 min at 37°C. The reaction was terminated with two volumes of methanol with 0.5% acetic acid and 40 µM stearic acid. Precipitated proteins and cell debris were removed by centrifugation ( $800 \times g$ , 10 min). The resulting supernatants were applied to a octadecyl reversed-phase disposable column (Chromabond C18, 100 mg; Macherey-Nagel, Duren, Germany). After washing, bound materials were eluted with 500  $\mu$ l methanol. The samples were analyzed in a reverse-phase (RP) HPLC system equipped with a Radial-Pak cartridge (5  $\times$  100 mm) packed with 4  $\mu$ m Novapak C18 material, guarded by Novapak C18 column (Waters associated; Milford, MA, USA). The mobile phase was methanol:water:trifluoroacetic acid (85:15:0.007) and the flow rate was 1.2 ml/min. Analysis was performed by comparing retention times with authentic standards. Radioactivity was detected with a  $\beta$ -RAM HPLC flow-through monitor system (Inus System Inc., USA). Quantitative determination was performed by peak area integration.

#### AA release from intact U937 cells

Cells were adjusted to  $2 \times 10^6$ /ml in RPMI 1640 and labelled with 0.2  $\mu$ Ci/ml of (5,6,8,9,11,12,14,15-<sup>3</sup>H)-AA (New England Nuclear, Germany) for 90 min at 37°C. The cells were washed twice to remove unincorporated <sup>3</sup>H-AA, and resuspended at  $1 \times 10^7$ /ml. Typically, 80 to 90% of the added <sup>3</sup>H-AA was incorporated into the cells. Cell culture was stopped at various times either with two volumes of 0.5% acetic acid and 40  $\mu$ M stearic acid in methanol, or with 5 ml acidified (HCl) Folch solution (choloroform: methanol, 2:1). Released fatty acids were extracted and analyzed by RP-HPLC. Alternatively, AA release was measured by GC-MS. Briefly, the reactions were stopped with 5 ml Folch solution. The samples were acidified by HCl and

resuspended in ether and analyzed by GC-MS.

butylhydroxytoluene was added as anti-oxidant. Deuterium-AA (d8-AA) (5.9 nM) was added as an internal standard and the samples were vigorously mixed. The chloroform phase was collected and dried under nitrogen. The fatty acids were resuspended in SP-HPLC mobile phase of hexane:isopropanol:acetic acid (99.5:0.5:0.02 vol) and separated by SP-HPLC on a Nucleosil 55 column. AA was collected, dried,

#### Statistical analysis

One way ANOVA and Mann Whitney-U were used as parametric and non-parametric tests to analyze the data.

#### Acknowledgements

This work has been supported by the Swedish Medical Research Council (O3X-07135), the Swedish Council for Work Life Research, the Lars Hiertas Foundation and the Karolinska Institute. We are indebted to Dr Grace Wong for the human TNF, Dr Anthony Ford-Hutchinson for the MK-886, Dr Lawrence G Garland for the BW A4C and BW B70C compounds, and Dr D Nicholson for DEVD-CHO.

#### References

- Agarwal ML, Larkin HE, Zaidi SIA, Mukhtar H and Oleinick NL (1993) Phospholipase activation triggers apoptosis in photosensitized mouse lymphoma cells. Cancer Res. 53: 5897 – 5902
- Aggarwal BB and Natarajan K (1996) Tumor necrosis factors: developments during the last decade. Eur. Cytokine Netw. 7: 93 124
- Anderson KM, Levin J, Jajeh A, Seed T and Harris JE (1993) Induction of apoptosis in blood cells from a patient with acute myelogenous leukemia by SC41661A, a selective inhibitor of 5-lipoxygenase. Prostaglandins Leukotrienes Essential Fatty Acids 48: 323–326
- Anderson KM, Seed T, Plate JMD, Jajeh A, Meng J and Harris JE (1995) Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis. Leukemia Res. 19: 789–801
- Beyaert R and Fiers W (1994) Molecular mechanisms of tumor necrosis factorinduced cytotoxicity. What do we understand and what we do not. FEBS letters 340: 9–16
- Brown DG, Sun XM and Cohen GM (1993) Dexamethasone-induced apoptosis involves cleavage of DNA to large fragments prior to internucleosomal fragmentation. J. Biol. Chem. 268: 3037–3039
- Capriotti AM, Furth EE, Arrasmith ME and Laposata M (1988) Arachidonatereleased upon agonist stimulation preferentially originates from arachidonate most recently incorporated into nuclear membrane phospholipids. J. Biol. Chem. 263: 10029 – 10034
- Chang DJ, Ringold GM and Heller RA (1992) Cell killing and induction of manganous superoxide dismutase by tumor necrosis factor- $\alpha$  is mediated by lipoxygenase metabolites of arachidonic acid. Biochem. Biophys. Res. Comm. 188: 538–546
- Chomczynski P and Saachi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-choloroform extraction. Analytical Biochemistry 162: 156–159
- Cissel DS, Murty M, Whipkey DL, Blaha JD, Graeber GM and Keeting PE (1996) Estrogen pretreatment increases arachidonic acid release by bradykinin stimulated normal human osteoblast-like cells. J. Cell Biochem. 60: 260 – 270
- Claesson HE, Odlander B and Jakobsson PJ (1992) Leukotriene B4 in the immune system. Int. J. Immunopharmac. 14: 441–449
- Claesson HE, Jakobsson PJ, Steinhilber D, Odlander B and Samuelsson B (1993) Expression of 5-lipoxygenase and biosynthesis of leukotriene B4 in human monomorphonuclear leukocytes. J. Lipid Med. 6: 15–22
- Dachary-Prigent J, Freyssinet JM, Pasquet JM, Carron JC and Nurden AT (1993) Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups. Blood 81: 2554–2565
- Dennis EA (1994) Diversity of group types, regulation, and function of phospholipase  $A_2$ . J. Biol. Chem. 269: 13057 13060

- Feltenmark S, Runarsson G, Larsson P, Jakobsson PJ, Björkholm M and Claesson HE (1995) Diverse expression of cytosolic phospholipase A<sub>2</sub>, 5-lipoxygenase and prostaglandin H synthase 2 in acute pre-B-lymphocytic leukaemia cells. Br. J. Haematol. 90: 585–594
- Ford-Hutchinson AW, Gresser M and Young RN (1994) 5-lipoxygenase. Annu. Rev. Biochem. 63: 383 417
- Fraser A and Evan G (1996) A license to kill. Cell 85: 781-784
- Garland LG and Hodgson ST (1994) Inhibition of leukotriene production by inhibitors of lipoxygenation. Adv. Prostaglandin Thromboxane Leukotriene Res. 22: 33 48
- Gilbert JJ, Stewart A, Courtney C-A, Fleming M-C, Reid P, Jackson CG, Wise A, Wakelam MJO and Harnett MM (1996) Antigen receptors on immature, but not mature, B and T cells are coupled to cytosolic phospholipase A<sub>2</sub> activation. J. Immunol. 156: 2054–2061
- Gillard J, Ford-Hutchinson AW, Chan C, Charleson S, Denis D, Foster A, Fortin R, Leger S, McFarlane CS, Morton H, Piechuta H, Riendeau D, Rouzer CA, Rokach J, Young R, MacIntyre DE, Peterson L, Bach T, Eiermann G, Hopple S, Humes J, Hupe L, Luell S, Metzger J, Meurer R, Miller DK, Opas E and Pacholok S (1989) L-663,536 (MK-886) (3-(1-(4-chlorobenzyl)-3-tbutyl-thio-5-isoprolyndol-2-yl)-2,2-dimethylpropanoic acid), a novel, orally active leukotriene byosinthesis inhibitor. Can. J. Physiol. Pharmacol. 67: 456-464
- Hamberg M, Svensson J and Samuelsson B (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. P.N.A.S. (USA) 72: 2994–2998
- Hollenback PW, Zilli DL and Laster SM (1992) Inhibitors of transcription and translation act synergistically with tumor necrosis factor to cause the activation of phospholipase A<sub>2</sub>. J. Biol. Chem. 267: 39–42
- Jakobsson PJ, Shaskin P, Larsson P, Feltenmark S, Odlander B, Aguilar-Santelises M, Jondal M, Biberfeld P and Claesson HE (1995) Studies on the regulation and localization of 5-lipoxygenase in human B-lymphocytes. Eur. J. Biochem. 232: 37–46
- Lowry O, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265–275
- MacEwan DJ (1996) Elevated cPLA<sub>2</sub> levels as a mechanism by which the p70 TNF and p75 NGF receptors enhance apoptosis. FEBS let. 379: 77–81
- Neale ML, Fiera RA and Matthews N (1988) Involvement of phospholipase  $A_2$  activation in tumor cell killing by tumor necrosis factor. Immunology 64: 81-85
- Newmeyer DD, Farschon DM and Reed JC (1994) Cell-free apoptosis in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell 79: 353–364
- Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Rayu SM, Smulson ME, Yamin TT, Yu VL and Miller DK (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37–43
- O'Donnell VB,Spycher S and Azzi A (1995) Involvement of oxidants and oxidantgenerating enzyme(s) in tumor necrosis factor<sub>z</sub>-mediated apoptosis: role for lipoxygenase pathway but not mitochondrial respiratory chain. Biochem. J. 310: 133–141
- Peters-Golden M and McNish RW (1993) Redistribution of 5-lipoxygenase and cytosolic phospholipase  $A_2$  to the nuclear fraction upon macrophage activation. Biochem. Biophys. Res. Comm. 196: 147–153

- Regier MK, DeWitt DL, Schindler MS and Smith WL (1993) Subcellular localisation of prostaglandin endoperoxide synthetase-2 in murine 3T3 cells. Arch. Biochem. Biophys. 301: 439–444
- Riendeau D, Guay J, Weech PK, Laliberte F, Yergey J, Li C, Desmarais S, Perrier H, Liu S, Nicoll-Griffith D and Street IP (1994) Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A<sub>2</sub>, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. J. Biol. Chem. 269: 15619–15624
- Schulze-Osthoff K, Walczak H, Dröge W and Krammer PH (1994) Cell nucleus and DNA fragmentation are not required for apoptosis. J. Cell. Biol. 127: 15–20
- Schütze S, Machleidt T and Krönke M (1992) Mechanism of tumor necrosis factor action. Semin. Oncol. 19(S4): 16–24
- Sorenson CM, Barry MA and Eastman A (1990) Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst. 82: 749 755
- Steller H (1995) Mechanisms and genes of cellular suicide. Science 267: 1445 1449 Sundstrom C and Nilsson K (1976) Establishment and characterisation of a human histiocytic lymphoma cell line (U937). Int. J. Cancer 17: 565 – 577
- Tanaka K, Itazaki H and Yoshida T (1992) Cinatrins a novel family of PLA<sub>2</sub> inhibitors. J. of Antibiotics 45: 50 – 55
- Tang DG, Chan YQ and Honn KV (1996) Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. PNAS (USA) 93: 5241 5246
- Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS and Dixit VM (1995) Yama/CPP32 $\beta$ , a mammalian homologue of CED-3, is a Crm-A-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801–809
- Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, Elliston KO, Ayala JM, Casano FJ, Chin J, Ding GJF, Egger LA, Gaffney EP, Limjuco G, Palyha OC, Raju SM, Rolando AM, Salley JP, Yamin TT, Lee TD, Shively JE, MacCross M, Mumford RA, Schmidt JA and Tocci MJ (1992) A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 356: 768–774
- Tsujii M and Dubois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493–501
- Vanags DM, Pörn-Ares MI, Copola S, Burgess DH and Orrenius S. (1996) Protease involvement in fodrin cleavage and phospatidylserine exposure in apoptosis. J. Biol. Chem. 271: 31075–31085
- Voelkel-Johnson C, Thorne TE and Laster SM (1996) Susceptibility to TNF in the presence of inhibitors of transcription or translation is dependent on the activity of cytosolic phospholipase A<sub>2</sub> in human melanoma tumor cells. J. Immunol. 156: 201–207
- Withnall MT, Pennington A and Wiseman D (1995) Characterisation of cytosolic phospholipase A<sub>2</sub> as mediator of the enhanced arachidonic acid release from dimethyl sulphoxide differentiated U937 cells. Biochem. Pharmacol. 50: 1893 1902
- Zhivotovsky B, Burgess DH and Orrenius S (1996) Proteases in apoptosis. Experientia 52: 968-978

486